Difference between revisions of "Olaratumab (Lartruvo)"
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Sarcoma" to "[[Category:Soft tissue sarcoma") |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | |||
*[[Soft tissue sarcoma|Soft tissue sarcoma]] | *[[Soft tissue sarcoma|Soft tissue sarcoma]] | ||
| Line 14: | Line 13: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *10/19/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526087.htm FDA approved] "for the treatment of patients with soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate." | + | *10/19/2016: [http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm526087.htm FDA approved] "for the treatment of patients with [[Soft tissue sarcoma|soft tissue sarcoma (STS)]] not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate." |
==Also known as== | ==Also known as== | ||
| − | LY3012207, IMC-3G3 | + | *'''Code names:''' LY3012207, IMC-3G3 |
| + | *'''Brand name:''' Lartruvo | ||
==References== | ==References== | ||
| Line 23: | Line 23: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | |||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
Revision as of 21:13, 16 November 2017
General information
Class/mechanism: Human IgG1 antibody that blocks the activity of platelet-derived growth factor receptor alpha (PDGFR-α). Olaratumab prevents binding of PDGF-AA and -BB ligands to PDGFR-α and blocks PDGF-AA, -BB, and -CC-induced receptor activation and downstream PDGFR-α pathway signaling, including the MAPK and PI3K pathways. PDGFR-α is a receptor tyrosine kinase expressed on mesenchymal origin cells, and signaling through PDGFR-α is involved in cell growth, chemotaxis, and mesenchymal stem cell differentiation.[1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Brief patient counseling information can be found in the Olaratumab (Lartruvo) package insert [1]
History of changes in FDA indication
- 10/19/2016: FDA approved "for the treatment of patients with soft tissue sarcoma (STS) not amenable to curative treatment with radiotherapy or surgery and with a histologic subtype for which an anthracycline-containing regimen is appropriate."
Also known as
- Code names: LY3012207, IMC-3G3
- Brand name: Lartruvo